体内研究 (In Vivo) |
Icosabutate (135 mg/kg;口服;每日一次;持续 5 周) 可改善雄性 ob/ob 小鼠的糖代谢与胰岛素敏感性,使 HOMA-IR 降低 87%,血浆丙氨酸转氨酶水平降低 33%。 Icosabutate (112 mg/kg;口服;每日一次;持续 20 周) 可减轻动脉粥样硬化模型小鼠的微泡性脂肪变性、肝脏炎症、纤维化、脂毒性脂质种类及氧化应激。 Icosabutate (45-135 mg/kg;口服;每日一次;4-8 周) 可剂量依赖性地减轻雄性 ob/ob 小鼠已形成的非酒精性脂肪性肝炎 (NASH) 中的肝脂肪变性、炎症、氧化应激、细胞凋亡及纤维化进展。 Icosabutate (112 mg/kg;口服;每日一次;持续 4 周) 可通过增强肝脏 VLDL 残粒清除率和 LDL-R 介导的胆固醇摄取,使高脂血症小鼠的血浆 TAG 和总胆固醇分别降低 70%和 68%。 Icosabutate (37.5 mg/kg;口服;每日一次;4.5 周,随后 15 mg/kg;口服;每日一次;12.5 周) 可使小鼠的总胆固醇暴露量降低约 29%,并减少动脉粥样硬化病变的形成、严重程度及病变数量。 Icosabutate (135 mg/kg;每日一次;持续 4 周) 给药 4 周后可显著改善肥胖 Zucker 大鼠的血糖控制,并降低其血浆甘油三酯、胆固醇及 AST 水平。
| Animal Model: |
ob/ob mice (male, 6-8 weeks old, genetic type 2 diabetes/insulin resistance model) |
| Dosage: |
135 mg/kg/d |
| Administration: |
p.o.; daily; 5 weeks |
| Result: |
Significantly reduced blood glucose by 50%, blood hemoglobin A1c by 47%, plasma insulin by 76%, and HOMA-IR by 87% versus control. Improved glucose tolerance, reducing the oral glucose tolerance test AUC0-120min by 60% versus control. Significantly reduced plasma alanine aminotransferase by 33% versus control. Did not affect body weight or plasma adiponectin levels. |
| Animal Model: |
APOE*3Leiden.CETP mice (male, 8-15 weeks old, high-fat/cholesterol-fed diet-induced NASH model) |
| Dosage: |
112 mg/kg/d |
| Administration: |
p.o.; daily; 20 weeks |
| Result: |
Significantly reduced microvesicular steatosis by 35%, hepatocellular hypertrophy by 82%, and hepatic inflammatory cell aggregates by 62% versus control. Significantly reduced serum amyloid A levels by 68%, hepatic collagen content by 32%, and fibrosis surface area by 26% versus control. Reduced hepatic concentrations of multiple lipotoxic lipid species including free fatty acids, diacylglycerols, bile acids, arachidonic acid, ceramides, and hydroxyeicosatetraenoic acids. Decreased hepatic oxidized glutathione (GSSG) while increasing the GSH/GSSG ratio. Activated regulators involved in lipid metabolism and energy production, and inhibited pro-inflammatory regulators including STAT1 and NFκB complex, as well as down-regulated fibrogenic genes in hepatic stellate cells via transcriptome analysis. |
| Animal Model: |
B6.V-Lepob/JRj (ob/ob) (male, 5 weeks old at arrival, NASH model via AMLN diet for 18 weeks with biopsy confirmation of fibrosis stage ≥1 and steatosis score ≥2; separate screening group fed AMLN diet for 15 weeks without biopsy) |
| Dosage: |
45 mg/kg bw/d; 90 mg/kg bw/d; 135 mg/kg bw/d (8-week treatment); 112 mg/kg bw/d (4-week screening study) |
| Administration: |
p.o.; daily; 8 weeks (45, 90, 135 mg/kg); p.o.; daily; 4 weeks (112 mg/kg) |
| Result: |
Reduced steatosis by 47%. Reduced hepatic TAG by 17% (45 mg/kg), 35% (90 mg/kg), 40% (135 mg/kg). Reduced plasma ALT by 32% (90 mg/kg) and 44% (135 mg/kg). Significantly reduced hepatic galectin-3 content (all doses). Reduced hepatic col1A1 % area by 27% (90 mg/kg) and total col1A1 by 32% (90 mg/kg) and 23% (135 mg/kg). Minimized fibrosis progression (90 mg/kg, post-pre biopsy col1A1 change). Reduced hepatic hydroxyproline (HYP) content in relative and total units (90 mg/kg and 135 mg/kg). Reduced hepatic α-SMA % area and total content (90 mg/kg and 135 mg/kg). Reduced post-pre biopsy α-SMA content (135 mg/kg). Reduced hepatic free fatty acids (FFAs), diacylglycerols (DAG), ceramides, total HETEs by 45% (90 mg/kg) and 51% (135 mg/kg), phosphatidylcholine-arachidonic acid (PC-AA) by 32% (90 mg/kg) and 42% (135 mg/kg), oxidised glutathione (GSSG), and oxidised phospholipids (oxPL) by 31% (90 mg/kg) and 46% (135 mg/kg). Increased hepatic GSH/GSSG ratio by 84% (135 mg/kg). Reduced hepatic apoptotic cell numbers by 41% (45 mg/kg), 29% (90 mg/kg), and 44% (135 mg/kg). Downregulated hepatic mRNA transcripts for genes regulating inflammatory responses (TNF-α, TGF-β1, TGFRβ, CCR2), stellate cell activation, fibrogenesis, and fibrolysis (112 mg/kg). |
| Animal Model: |
APOE*3Leiden.CETP transgenic (C57BL/6J background) (male, 7-10 weeks old, hyperlipidaemia model via 4-week run-in on Western-type diet with 0.25% cholesterol) |
| Dosage: |
112 mg/kg bw/d |
| Administration: |
p.o.; daily; 4 weeks |
| Result: |
Reduced plasma TAG by 70% (P <.001) and total cholesterol by 68% (P <.001); no effect on HDL cholesterol. Decreased plasma half-life of glycerol tri[3H]oleate by 40% (P =.008) and [14C]cholesteryl oleate by 52% (P =.001); increased hepatic uptake of both lipids. Increased hepatic LDL-R protein expression compared to controls (P ≤.05). Reduced hepatic cholesteryl ester content (P ≤.05) and faecal bile acid excretion (P ≤.05); no effect on hepatic free cholesterol, TAG, or faecal neutral sterol excretion. Upregulated hepatic gene pathways involved in fatty acid metabolism, β-oxidation, and (chole)sterol biosynthetic processes; downregulated pathways including complement activation, arachidonic acid cascade, innate immune response, and acute phase response. |
| Animal Model: |
APOE*3Leiden.CETP transgenic (C57BL/6J background) (female, 11-15 weeks old, atherosclerosis model via 4-week run-in on Western-type diet with 0.15% cholesterol) |
| Dosage: |
37.5 mg/kg bw/d (first 4.5 weeks); 15 mg/kg bw/d (final 12.5 weeks) |
| Administration: |
p.o.; daily; 17 weeks (37.5 mg/kg for 4.5 weeks, then 15 mg/kg for 12.5 weeks) |
| Result: |
Reduced total cholesterol exposure by ~29% compared to controls (P <.001). Reduced total aortic root lesion area by ~70% compared to controls (P <.001); reduced lesion number per cross section (P ≤.05). Increased undiseased aortic root segments to 44% (P <.01) and reduced severe type IV-V lesions to 18% compared to controls. |
| Animal Model: |
Obese Zucker rats |
| Dosage: |
135 mg/kg |
| Administration: |
daily; 4 weeks |
| Result: |
Reduced plasma triglycerides from 17.3 mM to 9.6 mM. Reduced plasma cholesterol from 10.1 mM to 5.4 mM. Reduced blood glucose from 11.8 mM to 7.2 mM. Reduced plasma insulin from 17.2 ng/mL to 9.4 ng/mL. Reduced HbA1c from 7.8% to 5.6%. Reduced HOMA-IR from 8.7 to 3.0. Increased plasma LDL-cholesterol from 0.4 mM to 1.5 mM. Reduced plasma AST from 167.3 U/L to 90.5 U/L. Caused no significant change in body weight, food intake, plasma VLDL-cholesterol, plasma ALT, or plasma adiponectin. |
|